JUPITER, Fla.--(BUSINESS WIRE)--Somahlution today announced today that it has received European market (CE) approval for DuraGraft, the first-in-class Endothelial Damage Inhibitor (EDI) that uniquely protects vascular endothelium function and its associated architecture. DuraGraft, used as a vascular conduit solution, is a pivotal step in successful coronary artery bypass graft (CABG) and peripheral bypass surgeries.
Help employers find you! Check out all the jobs and post your resume.
